Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMITRIPTYLINE HYDROCHLORIDE vs AVENTYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
Major depressive disorder (endogenous depression)
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Primarily hepatic via CYP2D6, CYP3A4, CYP1A2, and CYP2C19; active metabolite nortriptyline; undergoes demethylation, hydroxylation, and conjugation.
Extensively metabolized in the liver by cytochrome P450 enzymes (CYP2D6, CYP1A2, CYP2C19) via hydroxylation, N-demethylation, and N-oxidation; active metabolite: 10-hydroxynortriptyline. Metabolites are conjugated and excreted in urine.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Approximately 94-96%; primarily bound to alpha-1-acid glycoprotein (AAG), with minor binding to albumin and lipoproteins.
90-95% bound primarily to albumin.
10-20 L/kg (large Vd due to extensive tissue binding); clinical meaning: high tissue penetration, especially CNS, and slow redistribution from tissues.
15-30 L/kg; indicates extensive tissue penetration.
Oral: 30-60% due to extensive first-pass metabolism (CYP2C19, CYP3A4, CYP2D6); significant interindividual variability.
Oral: 30-60% due to first-pass metabolism.
GFR 10-50 m L/min: use 50% of normal dose; GFR <10 m L/min: use 25% of normal dose.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 50% of normal dose or every 12 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce dose by 75% with monitoring.
Adolescents: 10-50 mg daily in divided doses; children under 12 years (for enuresis): 6-10 years: 10-20 mg, 11+ years: 25-50 mg at bedtime.
Children 6-12 years: 10-30 mg/day in divided doses; >12 years: 25-50 mg/day in divided doses, maximum 100 mg/day. Weight-based: 1-2 mg/kg/day.
Start at 10-25 mg at bedtime; increase by 10-25 mg every 3-7 days as tolerated; maximum 75-100 mg daily; monitor for CNS and anticholinergic effects.
Initial dose 10-25 mg/day in divided doses, titrate slowly to maximum 100 mg/day; use with caution due to anticholinergic effects.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is recommended.
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Nortriptyline is not approved for use in pediatric patients.
Cardiotoxicity (QT prolongation, arrhythmias), serotonin syndrome, activation of mania/hypomania, angle-closure glaucoma, urinary retention, seizures, increased intraocular pressure, orthostatic hypotension, drowsiness, withdrawal symptoms upon abrupt discontinuation.
Suicidality: Monitor for worsening depression and suicidal thoughts, especially in young adults.,Cardiotoxicity: Risk of QT prolongation, arrhythmias, and sudden death; use with caution in patients with cardiovascular disease.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Anticholinergic effects: Use caution in patients with prostatic hypertrophy, narrow-angle glaucoma, or urinary retention.,Seizures: May lower seizure threshold.,Electroconvulsive therapy (ECT): Avoid concomitant use.,Hepatic impairment: Use with caution; metabolism may be reduced.,Hyperthyroidism: May potentiate cardiac toxicity.
Concurrent use with MAOIs (risk of serotonin syndrome), recent myocardial infarction, hypersensitivity to tricyclic antidepressants, during acute recovery phase of MI, use with cisapride or other QT-prolonging drugs.
Hypersensitivity to nortriptyline or any component of the formulation.,Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.,Acute recovery phase after myocardial infarction.,Concomitant use with cisapride, due to risk of QT prolongation.
Avoid alcohol and tyramine-rich foods (e.g., aged cheese, cured meats, soy sauce) due to risk of hypertensive crisis. Limit caffeine intake; may increase CNS stimulation. Grapefruit juice may increase plasma levels; avoid or limit consumption.
Avoid tyramine-rich foods (aged cheeses, cured meats, sauerkraut, soy products, tap beers) as concomitant use with MAOIs is contraindicated. However, nortriptyline itself has minimal tyramine interaction. Grapefruit juice may increase nortriptyline levels; avoid or limit intake. High-fiber foods may reduce absorption; take with a full glass of water.
First trimester: Limited data suggest a small increased risk of congenital malformations, particularly cardiovascular defects. Second trimester: No specific malformation risk, but possible effects on fetal growth. Third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and anticholinergic effects (constipation, urinary retention). Overall risk is low; benefits may outweigh risks in severe depression.
First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (irritability, feeding disorders) and anticholinergic effects (ileus, tachycardia).
Amitriptyline and its metabolite nortriptyline are excreted in breast milk with an M/P ratio of approximately 1.0 for amitriptyline. Infant daily dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in most infants; however, monitor for drowsiness, poor feeding. American Academy of Pediatrics considers amitriptyline compatible with breastfeeding.
Excreted in human milk; M/P ratio unknown. Limited data suggests low levels; use with caution, monitor infant for sedation and anticholinergic effects.
Pregnancy increases clearance of amitriptyline by 30-50% due to expanded plasma volume and enhanced hepatic metabolism. Serum levels may decrease, potentially requiring dose increase of 30-50% to maintain efficacy. Consider therapeutic drug monitoring (target trough 100-250 ng/m L) for dose titration. Postpartum dosing should be reduced to prepregnancy levels.
Increased hepatic metabolism in pregnancy may require dose adjustment; start at low end of dosing range, titrate based on response and tolerability.
Do not discontinue abruptly; taper over 2-4 weeks to prevent withdrawal symptoms. Use with caution in patients with cardiac conduction defects (prolongs QTc interval). Serum levels >500 ng/m L are associated with toxicity. Start at 10-25 mg at bedtime for neuropathic pain. May precipitate mania in bipolar disorder.
Aventyl (nortriptyline) is a secondary amine tricyclic antidepressant with less anticholinergic and sedative effects than tertiary amines like amitriptyline. It exhibits a narrow therapeutic window; therapeutic plasma levels are 50-150 ng/m L. Use with caution in patients with cardiovascular disease due to risk of QT prolongation. Avoid abrupt discontinuation to prevent withdrawal-like symptoms. Monitoring of plasma levels is recommended in elderly and those with hepatic impairment.
Take at bedtime to minimize daytime sedation.,Avoid alcohol and other CNS depressants.,Report symptoms of urinary retention, vision changes, or rapid heartbeat.,May cause dry mouth; use sugar-free gum or candy.,Avoid abrupt discontinuation; follow your doctor's tapering plan.,Notify your doctor if you experience suicidal thoughts or worsening depression.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of serotonin syndrome (agitation, hallucinations, fever) or suicidal thoughts.,May take 2-4 weeks to see full therapeutic effect.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store at room temperature away from moisture and light.
"Amitriptyline, a tricyclic antidepressant, may inhibit the metabolism of captopril, an ACE inhibitor, leading to increased serum concentrations of captopril. This elevation can potentiate captopril's antihypertensive effects and increase the risk of adverse effects such as hypotension, renal impairment, and hyperkalemia. Patients should be monitored closely for signs of exaggerated hypotensive response and electrolyte disturbances."
"Rifapentine, a potent inducer of cytochrome P450 (CYP) enzymes, specifically CYP3A4 and CYP2C19, significantly increases the hepatic metabolism of amitriptyline, a tricyclic antidepressant primarily metabolized by CYP2C19 and CYP3A4. This induction leads to markedly reduced plasma concentrations of amitriptyline and its active metabolite nortriptyline, potentially resulting in loss of antidepressant efficacy or relapse of depressive symptoms. Additionally, abrupt withdrawal of rifapentine without dose adjustment of amitriptyline may cause increased tricyclic levels and toxicity."
"Dapiprazole, an alpha-1 adrenergic receptor antagonist, and amitriptyline, a tricyclic antidepressant with significant anticholinergic properties, can have additive anticholinergic and sympatholytic effects when coadministered. This may lead to enhanced central nervous system depression, hypotension, urinary retention, and constipation. Patients should be monitored for excessive sedation, orthostatic hypotension, and anticholinergic toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMITRIPTYLINE HYDROCHLORIDE vs AVENTYL, answered by our medical review team.
AMITRIPTYLINE HYDROCHLORIDE is a Tricyclic Antidepressant that works by Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.. AVENTYL is a Tricyclic Antidepressant that works by Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMITRIPTYLINE HYDROCHLORIDE and AVENTYL depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMITRIPTYLINE HYDROCHLORIDE is: Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.. The standard adult dose of AVENTYL is: Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMITRIPTYLINE HYDROCHLORIDE and AVENTYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMITRIPTYLINE HYDROCHLORIDE is classified as Category C. First trimester: Limited data suggest a small increased risk of congenital malformations, particularly cardiovascular defects. Second trimester: No specific malformation risk, but . AVENTYL is classified as Category C. First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.